Comanche Biopharma Corp.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Comanche Biopharma Corp. - overview
Established
2020
Location
Concord, MA, US
Primary Industry
Biotechnology
About
Founded in 2020 by Mike Young and Thomas Scott Johnson, and based in Massachusetts, US, Comanche Biopharma Corp. operates as a biopharmaceutical company that develops siRNA therapy for the treatment of preeclampsia. In December 2023, Comanche Biopharma Corp. raised USD 37.
50 million in Series B funding co-led by New Enterprise Associates and Atlas Venture, with participation from GV (Google Ventures), F-Prime Capital, Lilly Asia Ventures (LAV), and Longview Healthcare Ventures. Comanche Biopharma specializes in developing an investigational siRNA medicine specifically aimed at addressing preterm preeclampsia, a severe pregnancy complication that poses significant risks to both mothers and infants. This therapeutic approach is designed to provide evidence-based solutions that cater to the urgent need for treatments in high-risk pregnancies. The company's primary target market includes healthcare providers, hospitals, and maternal-fetal medicine specialists who require reliable interventions to manage complications associated with pregnancy.
The company intends to use the December 2023 funding to initiate a clinical study of CBP-4888.
Current Investors
Atlas Venture, New Enterprise Associates, F-Prime Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.comanchebiopharma.com/
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.